"We have assembled an all-star team to deliver on our vision to become the world’s most trusted brand in regenerative aesthetics, longevity and wellness, driven by cutting-edge validated science".
Lionheart Health, Inc. announced today the appointments of Scott Hoots, Chad Hacker, and Tessa Sphar to its senior executive leadership team and Dr. Jwala Karnik to the Board of Directors.
“I am delighted to announce the addition of Scott, Chad, and Tessa to our executive leadership team and Dr. Jwala Karnik to our Board,” said Howard Leonhardt, Executive Chairman and co-CEO of Lionheart Health.
“We have worked diligently to build a best-in-class senior leadership team and board of directors as we hone our focus on opening up to 124 Lionheart Longevity & Wellness Medspas and EMS Fitness Studio locations worldwide over the next 60 months."
“Scott, Chad, Jwala, and Tessa are proven all-stars in our field of regenerative medicine and aesthetics. Scott led a team as CEO that opened over 200 regenerative medicine franchise locations. Chad helped lead Allergan Aesthetics into the digital marketing era and a $63 billion exit to Abbvie as VP of Consumer and Digital Marketing. Dr. Jwala Karnik newly elected Board Director was a key team member in helping to lead her previous firm to over $345 million in annual sales with a highly regarded Medspa skin treatment device. Tessa was the logistics leader in opening over 60 health and fitness franchise locations. This team brings an impressive track record into their new positions at Lionheart Health. We look forward to leveraging their expertise and insights as we grow Lionheart Health and advance our pipeline focused on regenerative aesthetics and healthspan longevity." Leonhardt further stated.
“I could not be more excited to be joining Lionheart Health a true technology innovator in our field,” said Scott Hoots, new co-CEO. “I look forward to working with the team to strengthen their ability to launch new locations with consistency. I share their commitment to mission purpose-based delivery of world-class one-of-a-kind patented technologies."
"What attracted me to Lionheart Health is their focus on the convergence of regenerative aesthetics and healthspan optimization," stated Dr. Jwala Karnik, Board Director. "I believe the future of beauty and healthcare is moving to personalized regenerative therapies. This is a great opportunity to join a proven core team that has led multiple products to industry leadership positions".
"Bioelectric protein expressions via homing stem cells to facial and neck tissue, building collagen, improving circulation and muscle tone, and improving elasticity are truly breakthroughs in skin regeneration. I joined Lionheart Health based on the promise of this technology to help improve the lives of millions" stated Chad Hacker, Board Director and Marketing Consultant
"Lionheart Health is determined to ensure every technology licensee delivers its patented technology platform to Medspa and fitness clinic clients in the best way possible. A commitment to world-class training. I am excited to join this team that has this mindset of doing things right from the beginning." stated Tessa Sphar, Lead Onboarding Specialist Consultant.
Lionheart Health, Inc. December of 2023 won the Allergan Aesthetics ULP Award for innovations in medical aesthetics and is an official entrant in the $101 million XPrize competition for healthspan extension.
LinkedIn Profiles New Members:
- Scott Hoots LinkedIn Profile >
- Chad Hacker LinkedIn Profile >
- Dr. Jwala Karnik LinkedIn Profile >
- Tessa Sphar LinkedIn Profile >
About Lionheart Health, Inc.
Lionheart Health, Inc. is focused on delivering best-in-class customized therapies for regenerative aesthetics and healthspan longevity extension primarily via highly trained licensed professionals. See Lionheart Longevity and Lionheart Health. Lionheart Health, Inc. is a spin-out of Leonhardt Ventures LLC that has been developing MedTech and biotech innovations for over 42 years. Over 600,000 patients have been treated with Leonhardt's inventions.
Contact email: [email protected]
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Lionheart Health, Inc,; the anticipated benefits of product candidates may not be realized, including expectations regarding therapeutic benefits, clinical potential and clinical development and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Lionheart Health may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Lionheart Health to timely and successfully achieve or recognize the anticipated benefits of commercialization, changes in applicable laws or regulation; the possibility that Lionheart Health may be adversely affected by other economic, business and/or competitive factors; Lionheart Health’s ability to advance product candidates on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring board; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop similar product and service treatments; maintaining or protecting intellectual property rights related to its product candidates; managing expenses; and raising the substantial additional capital needed, meeting timelines necessary, to continue development and market launch of product and service candidates Lionheart Health has proposed or may develop in the future. Lionheart Health may infringe patents of others and its own patents may be invalidated and patents pending may not be issued. Patent licenses may not be maintained. Lionheart Health anticipates that subsequent events and developments will cause Lionheart Health’s views to change sometime substantially. However, while Lionheart Health may elect to update these forward-looking statements at some point in the future, Lionheart Health specifically disclaims any obligation to do so, except as required by law.
Public Drive